세계의 모노클로널 항체 시장 점유율, 규모, 동향, 산업 분석 리포트 : 소스 유형별, 생산 유형별, 용도별, 최종사용자별, 지역별, 부문 예측(2022-2030년)

The global Monoclonal Antibodies market size is expected to reach USD 479.13 billion by 2030, according to a new study by Polaris Market Research. The report "Monoclonal Antibodies Market Share, Size, Trends, Industry Analysis Report, By Source Type (Chimeric, Murine, Humanized, Human), By Production Type (In Vivo, In Vitro), By Application, By End-use, By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides an analysis of future market growth.

The increasing uses of mAb therapies, rising government initiatives in infection control and management, and growing cancer incidences, with the demand for cost-effective biosimilar monoclonal antibodies, are the major factors driving the market. In addition, the high demand for biologics, the expansion of genomics R&D activities, and the introduction of technologically advanced genetic platforms like next-generation sequencing also spur market growth.

Furthermore, the monoclonal antibody market has grown due to the COVID-19 virus outbreak. Effective treatments are required due to the sudden increase in individuals with COVID-19 and the mortality risk associated with the illness. Additionally, due to their potential to reduce disease burden, numerous industry participants are consistently working to create novel mAb for the prevention and treatment of the COVID-19 virus. These antibodies are an efficient alternative for decreasing COVID-19, and the US FDA has given emergency use authorizations (EUA) for several of these antibodies.

Monoclonal Antibodies Market Report Highlights

In 2021, the human source category segment had the most significant proportion. Human monoclonal antibody product approvals and an increase in medicine launches contribute to the segment's growth. The market for this segment is predicted to grow due to human mAb in treating numerous infectious diseases.

The low levels of contamination provided by the method and the availability of improved biomanufacturing capabilities made in vitro production type the dominant type in 2021.

Due to the increasing number of mAb cancer therapies that have received approval, as well as growing public and scientific knowledge of these treatments, the oncology segment held the majority of the market in 2021.

Use of monoclonal antibodies for cancer treatment in hospitals and rising healthcare spending that favors the adoption of such medicines, hospitals made up the highest proportion of the end-use segment in 2021.

North America held the largest market share owing to Increasing Industry R&D spending and government financing for cancer research, which have aided in developing innovative monoclonal antibody treatments.

Major players operating in the industry include Abbott Laboratories, Amgen Inc, AstraZeneca plc, Bayer AG, Biogen Inc., Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc, Sanofi S.A., Thermo Fisher Scientific, Inc.,and Viatris Inc.

Polaris Market Research has segmented the Monoclonal Antibodies Market report based on raw material, type, technology, end-use, and region:

Monoclonal Antibodies, Source type Outlook (Revenue - USD Billion, 2018 - 2030)

Murine

Chimeric

Humanized

Human

Monoclonal Antibodies, Production Type Outlook (Revenue - USD Billion, 2018 - 2030)

In Vivo

In Vitro

Monoclonal Antibodies Application Outlook (Revenue - USD Billion, 2018 - 2030)

Oncology

Autoimmune Diseases

Infectious Diseases

Neurological Diseases

Others

Monoclonal Antibodies, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Specialty Centers

Others

Monoclonal Antibodies, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Monoclonal Antibodies Market Insights

• 4.1. Monoclonal Antibodies - Industry Snapshot
• 4.2. Monoclonal Antibodies Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Incidences Of Chronic Diseases
    • 4.2.1.2. Technological Advancements
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Cost Of Therapeutic Mabs
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Monoclonal Antibodies Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Monoclonal Antibodies Market, by Source Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
• 5.3. Murine
  • 5.3.1. Global Monoclonal Antibodies Market, by Murine, by Region, 2018 - 2030 (USD Billion)
• 5.4. Chimeric
  • 5.4.1. Global Monoclonal Antibodies Market, by Chimeric, by Region, 2018 - 2030 (USD Billion)
• 5.5. Humanized
  • 5.5.1. Global Monoclonal Antibodies Market, by Humanized, by Region, 2018 - 2030 (USD Billion)
• 5.6. Human
  • 5.6.1. Global Monoclonal Antibodies Market, by Human, by Region, 2018 - 2030 (USD Billion)

6. Global Monoclonal Antibodies Market, by Production Type

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
• 6.3. In Vivo
  • 6.3.1. Global Monoclonal Antibodies Market, by In Vivo, by Region, 2018 - 2030 (USD Billion)
• 6.4. In Vitro
  • 6.4.1. Global Monoclonal Antibodies Market, by In Vitro, by Region, 2018 - 2030 (USD Billion)

7. Global Monoclonal Antibodies Market, by Application

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
• 7.3. Oncology
  • 7.3.1. Global Monoclonal Antibodies Market, by Oncology, by Region, 2018 - 2030 (USD Billion)
• 7.4. Autoimmune Diseases
  • 7.4.1. Global Monoclonal Antibodies Market, by Autoimmune Diseases, by Region, 2018 - 2030 (USD Billion)
• 7.5. Infectious Diseases
  • 7.5.1. Global Monoclonal Antibodies Market, by Infectious Diseases, by Region, 2018 - 2030 (USD Billion)
• 7.6. Neurological Diseases
  • 7.6.1. Global Monoclonal Antibodies Market, by Neurological Diseases, by Region, 2018 - 2030 (USD Billion)
• 7.7. Others
  • 7.7.1. Global Monoclonal Antibodies Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Monoclonal Antibodies Market, by End-Use

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
• 8.3. Hospitals
  • 8.3.1. Global Monoclonal Antibodies Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
• 8.4. Speciality Centres
  • 8.4.1. Global Monoclonal Antibodies Market, by Speciality Centres, by Region, 2018 - 2030 (USD Billion)
• 8.5. Others
  • 8.5.1. Global Monoclonal Antibodies Market, by Others, by Region, 2018 - 2030 (USD Billion)

9. Global Monoclonal Antibodies Market, by Geography

• 9.1. Key findings
• 9.2. Introduction
  • 9.2.1. Monoclonal Antibodies Market Assessment, By Geography, 2018 - 2030 (USD Billion)
• 9.3. Monoclonal Antibodies Market - North America
  • 9.3.1. North America: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • 9.3.2. North America: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • 9.3.3. North America: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • 9.3.4. North America: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.3.5. Monoclonal Antibodies Market - U.S.
    • 9.3.5.1. U.S.: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.3.5.2. U.S.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.3.5.3. U.S.: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.3.5.4. U.S.: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.3.6. Monoclonal Antibodies Market - Canada
    • 9.3.6.1. Canada: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.3.6.2. Canada: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.3.6.3. Canada: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.3.6.4. Canada: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
• 9.4. Monoclonal Antibodies Market - Europe
  • 9.4.1. Europe: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • 9.4.2. Europe: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • 9.4.3. Europe: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • 9.4.4. Europe: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4.5. Monoclonal Antibodies Market - UK
    • 9.4.5.1. UK: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.5.2. UK: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.5.3. UK: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.5.4. UK: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4.6. Monoclonal Antibodies Market - France
    • 9.4.6.1. France: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.6.2. France: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.6.3. France: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.6.4. France: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4.7. Monoclonal Antibodies Market - Germany
    • 9.4.7.1. Germany: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.7.2. Germany: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.7.3. Germany: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.7.4. Germany: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4.8. Monoclonal Antibodies Market - Italy
    • 9.4.8.1. Italy: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.8.2. Italy: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.8.3. Italy: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.8.4. Italy: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4.9. Monoclonal Antibodies Market - Spain
    • 9.4.9.1. Spain: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.9.2. Spain: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.9.3. Spain: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.9.4. Spain: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4.10. Monoclonal Antibodies Market - Netherlands
    • 9.4.10.1. Netherlands: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.10.2. Netherlands: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.10.3. Netherlands: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.10.4. Netherlands: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.4.11. Monoclonal Antibodies Market - Russia
    • 9.4.11.1. Russia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.4.11.2. Russia.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.11.3. Russia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.4.11.4. Russia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
• 9.5. Monoclonal Antibodies Market - Asia Pacific
  • 9.5.1. Asia Pacific: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • 9.5.2. Asia Pacific: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • 9.5.3. Asia Pacific: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • 9.5.4. Asia Pacific: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.5.5. Monoclonal Antibodies Market - China
    • 9.5.5.1. China: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.5.5.2. China.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.5.3. China: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.5.5.4. China: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.5.6. Monoclonal Antibodies Market - India
    • 9.5.6.1. India: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.5.6.2. India.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.6.3. India: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.5.6.4. India: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.5.7. Monoclonal Antibodies Market - Japan
    • 9.5.7.1. Japan: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.5.7.2. Japan.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.7.3. Japan: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.5.7.4. Japan: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.5.8. Monoclonal Antibodies Market - Malaysia
    • 9.5.8.1. Malaysia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.5.8.2. Malaysia.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.8.3. Malaysia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.5.8.4. Malaysia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.5.9. Monoclonal Antibodies Market - Indonesia
    • 9.5.9.1. Indonesia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.5.9.2. Indonesia.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.9.3. Indonesia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.5.9.4. Indonesia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.5.10. Monoclonal Antibodies Market - South Korea
    • 9.5.10.1. South Korea: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.5.10.2. South Korea.: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.10.3. South Korea: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.5.10.4. South Korea: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
• 9.6. Monoclonal Antibodies Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • 9.6.2. Middle East & Africa: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • 9.6.3. Middle East & Africa: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • 9.6.4. Middle East & Africa: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.6.5. Monoclonal Antibodies Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.6.6. Monoclonal Antibodies Market - South Africa
    • 9.6.6.1. South Africa: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.6.6.2. South Africa: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.6.6.3. South Africa: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.6.6.4. South Africa: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.6.7. Monoclonal Antibodies Market - Israel
    • 9.6.7.1. Israel: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.6.7.2. Israel: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.6.7.3. Israel: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.6.7.4. Israel: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.6.8. Monoclonal Antibodies Market - UAE
    • 9.6.8.1. UAE: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.6.8.2. UAE: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.6.8.3. UAE: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.6.8.4. UAE: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
• 9.7. Monoclonal Antibodies Market - Latin America
  • 9.7.1. Latin America: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
  • 9.7.2. Latin America: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
  • 9.7.3. Latin America: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
  • 9.7.4. Latin America: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.7.5. Monoclonal Antibodies Market - Mexico
    • 9.7.5.1. Mexico: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.7.5.2. Mexico: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.7.5.3. Mexico: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.7.5.4. Mexico: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.7.6. Monoclonal Antibodies Market - Brazil
    • 9.7.6.1. Brazil: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.7.6.2. Brazil: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.7.6.3. Brazil: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.7.6.4. Brazil: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)
  • 9.7.7. Monoclonal Antibodies Market - Argentina
    • 9.7.7.1. Argentina: Monoclonal Antibodies Market, by Source Type, 2018 - 2030 (USD Billion)
    • 9.7.7.2. Argentina: Monoclonal Antibodies Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.7.7.3. Argentina: Monoclonal Antibodies Market, by Production Type, 2018 - 2030 (USD Billion)
    • 9.7.7.4. Argentina: Monoclonal Antibodies Market, by Application, 2018 - 2030 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Abbott Laboratories
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Amgen Inc
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. AstraZeneca plc
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Bayer AG
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Biogen Inc.
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Bristol Myers Squibb
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Daiichi Sankyo Company Limited
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Eli Lilly and Company
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. F. Hoffman-La Roche Ltd.
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. GlaxoSmithKline plc
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Johnson & Johnson Services, Inc.
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. Merck & Co., Inc.
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development
• 11.13. Merck KGaA
  • 11.13.1. Company Overview
  • 11.13.2. Financial Performance
  • 11.13.3. Product Benchmarking
  • 11.13.4. Recent Development
• 11.14. Novo Nordisk A/S
  • 11.14.1. Company Overview
  • 11.14.2. Financial Performance
  • 11.14.3. Product Benchmarking
  • 11.14.4. Recent Development
• 11.15. Novartis
  • 11.15.1. Company Overview
  • 11.15.2. Financial Performance
  • 11.15.3. Product Benchmarking
  • 11.15.4. Recent Development
• 11.16. Pfizer Inc
  • 11.16.1. Company Overview
  • 11.16.2. Financial Performance
  • 11.16.3. Product Benchmarking
  • 11.16.4. Recent Development
• 11.17. Sanofi S.A.
  • 11.17.1. Company Overview
  • 11.17.2. Financial Performance
  • 11.17.3. Product Benchmarking
  • 11.17.4. Recent Development
• 11.18. Thermo Fisher Scientific, Inc.
  • 11.18.1. Company Overview
  • 11.18.2. Financial Performance
  • 11.18.3. Product Benchmarking
  • 11.18.4. Recent Development
• 11.19. Viatris Inc.
  • 11.19.1. Company Overview
  • 11.19.2. Financial Performance
  • 11.19.3. Product Benchmarking
  • 11.19.4. Recent Development